Portfolio company Lipopeptide in strategic collaboration with PharmaResearch Products Ltd. 

Chalmers Ventures' portfolio company Lipopeptide announces a strategic collaboration with the South Korean biopharmaceutical company PharmaResearch Products Ltd. The two companies will collaborate on the clinical phase III development and marketing of PXL01, a novel therapeutic peptide for prevention of post-surgical adhesions after tendon- and nerve-repair procedures. According to the agreement PharmaResearch Products shall become the exclusive world-wide supplier of PXL01, which is Lipopeptide’s flagship program.

"It took us nearly ten years to develop this product and another two years to find the right partner. To see this project now advancing to clinical phase III together with a strong partner is extremely rewarding", comments Mattias Münnich, co-founder, entrepreneur and Chalmers School of entrepreneurship alumni.

"It is very satisfying as an inventor to see that your efforts soon may be of benefit to mankind", says Kjell Olmarker, founder and idea partner, Lipopeptide.

The company started at Chalmers School of entrepreneurship in 2005 under the name PharmaSurgics and was later merged to become Lipopeptide.

"This collaboration, with an international biopharmaceutical company, shows the width of our portfolio and that we can develop cutting edge technology over a wide spectrum of industries", says Linnéa Lindau, and congratulates Lipopeptide.

Contact information:

Mattias Münnich
Tfn +46 (0)733 - 837 933

På bild: Kjell Olmarker, MD, PhD, Professor